![]() ![]() "These findings provide a basis to specifically treat and remove mucus plugs as a strategy to improve lung health for COPD patients. "Studies using CT lung scans confirm that mucus plugs are highly prevalent in COPD patients and those with a high mucus plug burden have lower lung function, increased frequency of exacerbations, diminished quality of life, and increased risk of all-cause mortality," Prof Fahy explained. ![]() Prof John Fahy of UCSF and co-founder of Aer Therapeutics. Prof Fahy said Aer Therapeutics was taking using recent advances in the understanding of mucus plug biology and novel methods of quantifying mucus plugs using computed tomography (CT) to develop treatments. There are an estimated 5m COPD patients in the US with a mucus plug-high disease subtype that obstructs airways and that cannot be treated with conventional COPD treatments such as bronchodilators and supplemental oxygen. "Aer will continue to leverage this expertise in the development of AER-01 and other therapeutic candidates for the treatment of muco-obstructive lung diseases." "Our scientific founders led the pioneering research that uncovered mucus plugs as a key mechanism of disease in COPD, and their laboratories worked together to discover AER-01 as a novel mucolytic treatment. "We are excited to introduce Aer Therapeutics as a company dedicated to delivering a therapeutic solution to patients with COPD who have severe airway obstruction caused by mucus plugs," said Jim Shaffer, president and CEO of Aer Therapeutics. Prof Fahy's laboratory at USCF developed AER-01 with Prof Oscarson's glycochemistry laboratory at UCD in collaboration with Prof Anne Marie Healy's pharmaceutical technology laboratory at Trinity College Dublin (TCD). The company was founded from Prof John Fahy of UCSF, who is originally from Dublin, and Prof Stefan Oscarson of the UCD School of Chemistry. The funding will be used to advance the development of AER-01, its novel inhaled small molecule mucolytic drug designed to liquify mucus plugs in the lungs of patients with chronic obstructive pulmonary disease (COPD).Īer Therapeutics, which is headquartered in North Carolina and spun out of UCD and the University of California, San Francisco (UCSF), plans to initiate a first-in-human Phase 1 clinical trial of AER-01 in mid-2023. ![]() Aer Therapeutics, a UCD biopharma spin-out developing inhaled treatments for lung diseases has closed a $36m Series A financing round led by leading science investors including Canaan, OrbiMed, and Hatteras Venture Partners. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |